EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma

Qiyu Zhu, Ting Wang, Yifu Shi, Xiuya Zhou, Dingbang Liu, Junru Chen, Haoyang Liu, Fengnian Zhao, Chenhao Xu, Yuntian Chen, Jiayu Liang, Ni Chen iD und 3 weitere

The Journal of Pathology: Clinical Research · 2025

DOI: 10.1002/2056-4538.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Qiyu Zhu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, PR China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Carcinoma, Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University, Science and Technology Support Program of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ductal adenocarcinoma of the prostate (DA) is relatively rare and highly co‐existent with prostate adenocarcinoma (AC). This study aimed to investigate the distinctive genomic profiles of patients with DA compared to those without. Blood samples were obtained from 144 patients (36 with DA and 108 without DA) who were diagnosed from 2017 to 2023 at West China Hospital. We performed cell‐free DNA sequencing to investigate the genomic differences between patients with DA [DA(+)] and those without [DA(−)], and explored the potential associations between their mutational status and prognosis. Pathogenic and likely pathogenic alterations were included for analysis. We identified that AR pathway [16/36 (44.4%) versus 24/108 (22.2%), p = 0.017] and WNT pathway [6/36 (16.7%) versus 5/108 (4.6%), p = 0.029] mutations were significantly enriched in DA(+) compared to DA(−) patients. Mutation of FOXA1 , as a key component of the AR pathway, demonstrated markedly higher prevalence in the DA(+) over the DA(−) cohort [25% (9/36) versus 4.6% (5/108), p = 0.0012]. The DNA damage repair mutation rate and the homologous recombination repair deficiency scores appeared to be comparable between the DA(+) and DA(−) patients. In the metastatic population, DA was characterized by a higher speckle‐type POZ protein ( SPOP ) mutation rate. TP53 mutation was associated with a deteriorating prognosis for both DA(+) and DA(−) patients in terms of castration‐free survival. In conclusion, our findings provide further genomic insights into prostate cancer with ductal morphology and are instructive for the diagnosis and treatment of DA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorCarcinoma, DuctalHumansMaleAgedMiddle AgedLiquid BiopsyMutationHepatocyte Nuclear Factor 3-alphaGenomicsAged, 80 and overPrognosis

Stichwörter der Autor:innen

AR pathwayFOXA1ductal adenocarcinoma

Substanzen

Biomarkers, TumorFOXA1 protein, humanHepatocyte Nuclear Factor 3-alpha

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, PR China.
  • Department of Nursing, West China Hospital, Sichuan University, Chengdu, PR China.
  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, PR China.
  • Department of Radiology, West China Hospital, Sichuan University, Chengdu, PR China.

ORCID-Profile: Ni Chen

Förderung

  • 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
  • Science and Technology Support Program of Sichuan Province
  • National Natural Science Foundation of China
  • Clinical and Translational Medicine Research Project, Chinese Academy of Medical Sciences
  • Beijing Bethune Charitable Foundation
  • Postdoctoral Research and Development Fund of West China Hospital of Sichuan University

Zitieren

APA

Zhu, Q., Wang, T., Shi, Y., Zhou, X., Liu, D., Chen, J., Liu, H., Zhao, F., Xu, C., Chen, Y., Liang, J., Chen, N., Shen, P., Zeng, H., & Zhao, J. (2025). Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70026

Vancouver

Zhu Q, Wang T, Shi Y, Zhou X, Liu D, Chen J, et al. Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70026

BibTeX
@article{Zhu2025,
  author = {Zhu, Qiyu and Wang, Ting and Shi, Yifu and Zhou, Xiuya and Liu, Dingbang and Chen, Junru and Liu, Haoyang and Zhao, Fengnian and Xu, Chenhao and Chen, Yuntian and Liang, Jiayu and Chen, Ni and Shen, Pengfei and Zeng, Hao and Zhao, Jinge},
  title = {Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2025},
  doi = {10.1002/2056-4538.70026}
}
Kostenlos starten →